Table 1 Patient demographics and baseline characteristics
Characteristic | Total (N = 127) |
|---|---|
Median age, years (range) | 67 (24–88) |
Age ≥75 years, n (%) | 30 (23.6) |
Male, n (%) | 76 (59.8) |
Race, n (%) | |
White | 61 (48.0) |
Asian | 53 (41.7) |
Not reported | 13 (10.2) |
Geographic region, n (%) | |
Asia–Pacific | 64 (50.4) |
Europe | 52 (40.9) |
North America | 11 (8.7) |
ECOG performance status, n (%) | |
0 | 41 (32.3) |
1 | 86 (67.7) |
Ann Arbor stage, n (%) | |
I–II | 24 (18.9) |
III–IV | 103 (81.1) |
International Prognostic Index, n (%) | |
Low (0–1) | 19 (15.0) |
Low–intermediate (2) | 36 (28.3) |
High–intermediate (3) | 41 (32.3) |
High (4–5) | 30 (23.6) |
Missing | 1 (0.8) |
Cell of origin, n (%) | |
GCB | 43 (33.9) |
ABC or non-GCB | 56 (44.1) |
Unclassified or missing | 28 (22.0) |
DLBCL subtype, n (%) | |
DLBCL, de novo | 96 (75.6) |
DLBCL, transformed (Richter’s) | 7 (5.5) |
DLBCL, transformed (non-Richter’s) | 24 (18.9) |
DLBCL cytogenetic status, n (%) | |
Double hit | 5 (3.9) |
Triple hit | 6 (4.7) |
Bulky disease, n (%) | 28 (22.0) |
Median prior lines of therapy (range), n | 2 (2–8) |
Prior lines of antilymphoma treatment, n (%) | |
2 | 67 (52.8) |
3 | 34 (26.8) |
≥4 | 26 (20.5) |
Prior ASCT, n (%) | 22 (17.3) |
R/R status, n (%) | |
Primary refractory | 70 (55.1) |
Refractory to any prior line of therapy | 115 (90.6) |
Refractory to last line of therapy | 110 (86.6) |
Refractory to anti-CD20 antibody in any line | 99 (78.0) |
Refractory to an alkylator in any line | 88 (69.3) |
Double refractory to alkylator and anti-CD20 antibody in any line | 82 (64.6) |
